Leukemias induced by altered TRK-signaling are sensitive to mTOR inhibitors in preclinical models

Annals of Hematology

Volumn 90, Issue 3, 2011, Pages 283-292

  Rhein, Mathias ^a   Schwarzer, Adrian ^a   Yang, Min ^a   Kaever, Volkhard ^a   Brugman, Martijn ^a   Meyer, Johann ^a   Ganser, Arnold ^a   Baum, Christopher ^a   Li, Zhixiong ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute leukemia; mTOR; Resistance; TRKs

Indexed keywords

EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN S6; PROTEIN TYROSINE KINASE; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME REACTIVATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SURVIVAL TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INDUCTION; HUMANS; LEUKEMIA, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEINS; RECEPTOR, TRKB; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 79951679777     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1065-3     Document Type: Article

References (35)

1. L Tickenbrock C Muller-Tidow WE Berdel H Serve 2006 Emerging Flt3 kinase inhibitors in the treatment of leukaemia Expert Opin Emerg Drugs 11 153 165 1:CAS:528:DC%2BD28XhvVKgtbw%3D 10.1517/14728214.11.1.153 16503833
2. AM Martelli C Evangelisti F Chiarini C Grimaldi L Manzoli JA McCubrey 2009 Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia Expert Opin Investig Drugs 18 1333 1349 1:CAS:528:DC%2BD1MXpslOltbg%3D 10.1517/14728220903136775 19678801
3. M Laplante DM Sabatini 2009 mTOR signaling at a glance J Cell Sci 122 3589 3594 1:CAS:528:DC%2BD1MXhsVKitrvP 10.1242/jcs.051011 19812304
4. AY Choo SO Yoon SG Kim PP Roux J Blenis 2008 Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation Proc Natl Acad Sci USA 105 17414 17419 1:CAS:528:DC%2BD1cXhsVWns7rJ 10.1073/pnas.0809136105 18955708
5. CC Thoreen SA Kang JW Chang Q Liu J Zhang Y Gao LJ Reichling T Sim DM Sabatini NS Gray 2009 An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1 J Biol Chem 284 8023 8032 1:CAS:528:DC%2BD1MXjtVSmtLY%3D 10.1074/jbc.M900301200 19150980
6. MR Janes JJ Limon L So J Chen RJ Lim MA Chavez C Vu MB Lilly S Mallya ST Ong M Konopleva MB Martin P Ren Y Liu C Rommel DA Fruman 2010 Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor Nat Med 16 205 213 1:CAS:528:DC%2BC3cXltlCnsQ%3D%3D 10.1038/nm.2091 20072130
7. Z Zeng D dos Sarbassov IJ Samudio KW Yee MF Munsell C Ellen Jackson FJ Giles DM Sabatini M Andreeff M Konopleva 2007 Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML Blood 109 3509 3512 1:CAS:528:DC%2BD2sXksFWhs78%3D 10.1182/blood-2006-06-030833 17179228 (Pubitemid 46572543)
8. C Recher O Beyne-Rauzy C Demur G Chicanne C Dos Santos VM Mas D Benzaquen G Laurent F Huguet B Payrastre 2005 Antileukemic activity of rapamycin in acute myeloid leukemia Blood 105 2527 2534 1:CAS:528:DC%2BD2MXisFSktbk%3D 10.1182/blood-2004-06-2494 15550488 (Pubitemid 40387055)
9. S Descamps V Pawlowski F Revillion L Hornez M Hebbar B Boilly H Hondermarck JP Peyrat 2001 Expression of nerve growth factor receptors and their prognostic value in human breast cancer Cancer Res 61 4337 4340 1:CAS:528:DC%2BD3MXktlSqurc%3D 11389056 (Pubitemid 32685755)
10. LM McGregor BK McCune JR Graff PR McDowell KE Romans GD Yancopoulos DW Ball SB Baylin BD Nelkin 1999 Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression Proc Natl Acad Sci USA 96 4540 4545 1:CAS:528:DyaK1MXjs1ylsLY%3D 10.1073/pnas.96.8.4540 10200298 (Pubitemid 29190372)
11. A Nakagawara M Arima-Nakagawara NJ Scavarda CG Azar AB Cantor GM Brodeur 1993 Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma N Engl J Med 328 847 854 1:STN:280: DyaK3s7otVyltA%3D%3D 10.1056/NEJM199303253281205 8441429 (Pubitemid 23084339)
12. Z Li J Dullmann B Schiedlmeier M Schmidt C von Kalle J Meyer M Forster C Stocking A Wahlers O Frank W Ostertag K Kuhlcke HG Eckert B Fehse C Baum 2002 Murine leukemia induced by retroviral gene marking Science 296 497 1:CAS:528:DC%2BD38XjtFamsLk%3D 10.1126/science.1068893 11964471 (Pubitemid 34408663)
13. GW Reuther QT Lambert MA Caligiuri CJ Der 2000 Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia Mol Cell Biol 20 8655 8666 1:CAS:528:DC%2BD3MXitFGkurk%3D 10.1128/MCB.20.23.8655-8666.2000 11073967 (Pubitemid 32245899)
14. J Meyer M Rhein B Schiedlmeier O Kustikova C Rudolph K Kamino T Neumann M Yang A Wahlers B Fehse GW Reuther B Schlegelberger A Ganser C Baum Z Li 2007 Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, deltaTrkA Leukemia 21 2171 2180 1:CAS:528: DC%2BD2sXhtVGmsLfF 10.1038/sj.leu.2404882 17673903 (Pubitemid 47423807)
15. Q Liu J Schwaller J Kutok D Cain JC Aster IR Williams DG Gilliland 2000 Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia Embo J 19 1827 1838 1:CAS:528:DC%2BD3cXivVKltrw%3D 10.1093/emboj/19.8.1827 10775267 (Pubitemid 30204394)
16. S Newrzela K Cornils Z Li C Baum MH Brugman M Hartmann J Meyer S Hartmann ML Hansmann B Fehse D von Laer 2008 Resistance of mature T cells to oncogene transformation Blood 112 2278 2286 1:CAS:528:DC%2BD1cXhtFCrurnO 10.1182/blood-2007-12-128751 18566328
17. Z Li G Beutel M Rhein J Meyer C Koenecke T Neumann M Yang J Krauter N von Neuhoff M Heuser H Diedrich G Gohring L Wilkens B Schlegelberger A Ganser C Baum 2009 High-affinity neurotrophin receptors and ligands promote leukemogenesis Blood 113 2028 2037 1:CAS:528:DC%2BD1MXivVaqtrs%3D 10.1182/blood-2008-05-155200 19059881
18. PO Krutzik GP Nolan 2003 Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events Cytometry A 55 61 70 10.1002/cyto.a.10072 14505311 (Pubitemid 37522508)
19. Q Wu K Kiguchi T Kawamoto T Ajiki J Traag S Carbajal L Ruffino H Thames I Wistuba M Thomas KM Vasquez J DiGiovanni 2007 Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model Cancer Res 67 3794 3800 1:CAS:528:DC%2BD2sXkt1Kit7k%3D 10.1158/0008-5472.CAN-06-3214 17440093 (Pubitemid 46762166)
20. HC Morse 3rd MR Anver TN Fredrickson DC Haines AW Harris NL Harris ES Jaffe SC Kogan IC MacLennan PK Pattengale JM Ward 2002 Bethesda proposals for classification of lymphoid neoplasms in mice Blood 100 246 258 1:CAS:528:DC%2BD38XltF2rtr8%3D 10.1182/blood.V100.1.246 12070034 (Pubitemid 35177454)
21. Q Xu JE Thompson M Carroll 2005 mTOR regulates cell survival after etoposide treatment in primary AML cells Blood 106 4261 4268 1:CAS:528:DC%2BD2MXhtlaltrrF 10.1182/blood-2004-11-4468 16150937 (Pubitemid 41775935)
22. M Guba GE Koehl E Neppl A Doenecke M Steinbauer HJ Schlitt KW Jauch EK Geissler 2005 Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer Transpl Int 18 89 94 1:CAS:528: DC%2BD2MXksFCgtLo%3D 10.1111/j.1432-2277.2004.00026.x 15612989 (Pubitemid 41742951)
23. PD Knott H Tamai M Strome F Van Lente S Shu 2007 RAD inhibition of sarcoma growth: implications for laryngeal transplantation Am J Otolaryngol 28 375 378 1:CAS:528:DC%2BD2sXht1GlurzF 10.1016/j.amjoto.2006.11.003 17980767 (Pubitemid 350016428)
24. C Nishioka T Ikezoe J Yang S Gery HP Koeffler A Yokoyama 2009 Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells Int J Cancer 125 1710 1720 1:CAS:528: DC%2BD1MXpsVKmsLg%3D 10.1002/ijc.24472 19507250
25. C Matsuda T Ito J Song T Mizushima H Tamagawa Y Kai Y Hamanaka M Inoue T Nishida H Matsuda Y Sawa 2007 Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis Clin Exp Immunol 148 348 359 1:CAS:528:DC%2BD2sXmt1emsLo%3D 10.1111/j.1365-2249.2007. 03345.x 17437423 (Pubitemid 46587591)
26. OH Yilmaz R Valdez BK Theisen W Guo DO Ferguson H Wu SJ Morrison 2006 Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells Nature 441 475 482 1:CAS:528:DC%2BD28XkvVykurY%3D 10.1038/nature04703 16598206 (Pubitemid 44050144)
27. R Crazzolara A Cisterne M Thien J Hewson R Baraz KF Bradstock LJ Bendall 2009 Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia Blood 113 3297 3306 1:CAS:528: DC%2BD1MXksFWqsbc%3D 10.1182/blood-2008-02-137752 19196656
28. DT Teachey DA Obzut J Cooperman J Fang M Carroll JK Choi PJ Houghton VI Brown SA Grupp 2006 The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL Blood 107 1149 1155 1:CAS:528:DC%2BD28Xht1OntLo%3D 10.1182/blood-2005-05-1935 16195324 (Pubitemid 43156317)
29. KE O'Reilly F Rojo QB She D Solit GB Mills D Smith H Lane F Hofmann DJ Hicklin DL Ludwig J Baselga N Rosen 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 1500 1508 10.1158/0008-5472.CAN-05-2925 16452206 (Pubitemid 43259931)
30. A Carracedo L Ma J Teruya-Feldstein F Rojo L Salmena A Alimonti A Egia AT Sasaki G Thomas SC Kozma A Papa C Nardella LC Cantley J Baselga PP Pandolfi 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J Clin Invest 118 3065 3074 1:CAS:528:DC%2BD1cXhtV2isb3P 18725988
31. D Xing S Orsulic 2005 A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance Proc Natl Acad Sci USA 102 6936 6941 1:CAS:528:DC%2BD2MXksVKnsrw%3D 10.1073/pnas.0502256102 15860581 (Pubitemid 40675420)
32. RN Pearse SL Swendeman Y Li D Rafii BL Hempstead 2005 A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival Blood 105 4429 4436 1:CAS:528:DC%2BD2MXks12isLs%3D 10.1182/blood-2004-08-3096 15657181 (Pubitemid 40720791)
33. EJ Brown PA Beal CT Keith J Chen TB Shin SL Schreiber 1995 Control of p70 s6 kinase by kinase activity of FRAP in vivo Nature 377 441 446 1:CAS:528:DyaK2MXos1Slsro%3D 10.1038/377441a0 7566123
34. G Armengol F Rojo J Castellvi C Iglesias M Cuatrecasas B Pons J Baselga S Ramon y Cajal 2007 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications Cancer Res 67 7551 7555 1:CAS:528:DC%2BD2sXptVGls70%3D 10.1158/0008-5472.CAN-07-0881 17699757 (Pubitemid 47281345)
35. DD Sarbassov SM Ali S Sengupta JH Sheen PP Hsu AF Bagley AL Markhard DM Sabatini 2006 Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB Mol Cell 22 159 168 1:CAS:528:DC%2BD28Xkt1GmtLo%3D 10.1016/j.molcel.2006.03.029 16603397